Chemotherapy and immunotherapy for disseminated malignant melanomas;Chimiotherapie et immunotherapie des melanomes malins metastatiques

Presse Medicale

Volumn 25, Issue 35, 1996, Pages 1690-1697

  Benhammouda, A ^a   Auclerc, G ^a   Coeffic, D ^a   Weil, M ^a   Nizri, D ^a   Soubrane, C ^a   Banzet, P ^a,b   Khayat, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; NITROSOUREA; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MELANOMA; METASTASIS; PROGNOSIS; REVIEW; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 0030590677     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Carbone PP, Costello W. Eastern Cooperative oncology Group studies with DTIC (NSC-45388). Cancer Treat Rep 1976 ; 60:193-8.
2. Ahmann DL. Nitrosoureas in the management of dissemiated malignant melanoma. Cancer Treat Rep 1976 ; 60:747.
3. Wasserman TH, Slavik M, Carter SK. Review of CCNU in clinical cancer therapy. Cancer Treat Rev 1974 ; 1:131.
4. Nolte H, Lindgaard-Nedsen E, Bloomquist E et al. Phase II evaluation of tauromustine in disseminated malignant melanoma. Proc Am Soc Clin Oncol 1988 ; 7:249.
5. Khayat D, Lokiec F, Bizzari JP et al. Phase I clinical study of the new amino acid-linked nitrosourea S10036 administered on a weekly schedule. Cancer Res. 1987 ; 47:6782.
6. Evans L, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 1987 ; 71:171.
7. Smart CR, Ottoman RE, Rochin DB et al. Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases. Cancer Chemother Rep 1968 ; 52:733.
8. Bleechan NM, Jellifee AM. Vinblastine sulfate in the treatment of malignant disease. Br J Cancer 1965 ; 19:268.
9. Mayol XF, Beltran J, Rubio-Bazan R et al. Multicenter phase II trial with 5-day continuous infusion of vindesine in metastatic malignant melanoma. Cancer Treat Rep. 1983 ; 68:1199.
10. Legha SS, Ring S, Papadopoulos N et al. A phase II Trial of taxol in metastatic melanoma. Cancer 1990 ; 65:2478.
11. Malden LT, Coates AS, Milton GW et al. Mitolactol chemotherapy for malignant melanoma. Cancer Treat Rev 1984 ; 68:1045.
12. Friustaci S, Gafprini G, Galligioni E et al. Phase II trial of Esorubicin in patients with advanced melanoma. Cancer Treat Rep 1987 ; 71:325.
13. Feun LG, Gonzalez R, Savaraj N et al. Phase II study of piritrexim in metastatic melanoma using intermittent, low dose administration. J Clin Oncol 1991 ; 9:464.
14. Marsoni S, Hoth D, Simon R. Clinical drug development an analysis of phase II trials, 1970-1985. Cancer Treat Rep 1987 ; 71:71.
15. Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990 ; 66:1873.
16. Khayat D, Lokiee F, Bizzari JP et al. Phase I clinical study of the new amino acid-linked nitrosourea S10036 administered a weekly schedule. Cancer Res 1987 ; 47:6782.
17. Al-Sarraf M, Fletcher W, Oishi N et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melnaoma: A Southwest Oncology Group Study. Cancer Treat Rep 1982 ; 66:31.
18. Mortimer JE, Chestnut T, Higano CS, Goodman G. High dose cisplatin in metastatic melanoma: Comparison of two schedules. Proc Am Soc Clin Oncol 1988 ; 7:254.
19. Kim S, McClay E, Kirmani S et al. Biweekly intravenous (IV) cisplatin with sodium thiosulfate. Proc Am Soc Clin Oncol 1990 ; 9:88.
20. Goodnight JE Jr, Moseley HS, Eilber FE et al. Cis-dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanome. Cancer Treat Rep 1979 ; 63:2005.
21. Glover D, Glick J, Weiler C, Fox K, Grabelsky S, Guerry D. High dose cisplatinum (DDP) and WR-2721 in metastatic melanoma. Proc Am Soc Clin Oncol 1988 ; 7:247.
22. Ramirez G, Wilson W, Grage T et al. Phase II evaluation of 1,3-bis (2-chloroethyl-nitrosourea) (BCNU ; NSC-409962) in patients with solid tumors. Cancer Chemother Rep 1972 ; 56:787.
23. Ahman DL. Nitrosoureas in the management of disseminated malignant melanoma. Cancer Treat Rep 1976 ; 60:747.
24. Holland JF, Scharlay C, Gailanai S et al. Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Res 1964 ; 32:19.
25. Shaw RK, Brunner JA Clinical evaluation of vincristine (NSC-67574). Cancer Chemother Rep 1964 ; 42:45.
26. Wiernik PH, Schwartz EL, Einzig A et al. Phase I trial of taxol given as a 24-hour infusion every 2 days: Responses observed in metastatic melanoma. J Clin Oncol 1987 ; 5:1232.
27. Einzig A, Trump DL, Sasloff J et al. Phase II pilot study of taxol in patients with malignant melanoma. Proc Am Soc Clin Oncol 1988 ; 7:249.
28. Legha SS, Ring S, Papadopoulos N et al. A phase II trial of taxol in metastatic melanoma. Cancer 1990 ; 65:2478.
29. Andrews NC, Weiss AJ, Ansfield FJ et al. Phase I study of dibromoduleitol (NSC-104800). Cancer Chemother Rep 1971 ; 55:61.
30. Andrews NC, Weiss AJ, Wilson W et al. Phase II study of dibromoduleitol (NSC-104800). Cancer Chemother Rep 1974 ; 58:653.
31. Hill GJ II, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy. Cancer 1984 ; 53:1299.
32. Avril MF, Bonneterre J, Cupissol D et al. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992 ; 11:1807-11.
33. Bar MH, Szol M, Atkins MB et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine actived killer cells. J Clin Oncol 1990 ; 7:1138.
34. Khayat D, Borel C, Benhammouda A et al. Active Three drugs (foemustine, dacarbazine, vindesine) outpatient combination in advanced malignant melanoma. Proc Am Ass Cancer Res 1992 ; 33:abstr 1366.
35. Semb KA, Aamdal S, Bohmann T, Lucas C, Gerard B. Phase II study of fotemustine (F), cisplatin (CDDP) and tamoxifen (TAM) in metastatic malignat melanoma (MMM). 3rd international Conference on Melanoma, Venise, 1993.
36. Rixe O, Borel Ch, Paraiso D et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Melanoma Research 1995 ; 5:419-24.
37. Kerr R, Rippen P, Mennel R et al. Treatment of metastatic malignant melanoma with a combination of interferon-α2a and dacarbazine. Proc Am Soc Clin Soc Clin Oncol 1989 ; 8:288
38. Hill H JC, Metter GE, Krementz ET et al. DTIC and combination therapy for melanoma II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine. Cancer Treat Rep 1979 ; 63:1989.
39. Gunderson S Dacarbazine, vindesine and cisplatin combination chemotherapy in advanced malignant melanoma; Cancer Trent Rep 1987 ; 71:997.
40. McClay EF, Mastrangelo MJ, Bellet RE. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987 ; 71:465.
41. Krown SE, Burk MW, Kirkwood JM et al. Human leukocyte (α) interferon in metastic malignant melanoma : the American Cancer Society phase II trial. Cancer Treat Rep 1984 ; 68:723.
42. Dutcher JP, Creekmore S, Weiss GR et al. Phase II study of high dose interleukin-2 and lymphokine activated killer cells in patients with melanoma. Proc Am Soc Clin Oncol 1987 ; 6:970.
43. Bar MH, Szol M, Atkins MB et al. Metastic melanoma treated with combined bolus and continuous infusion interleukin-2 lymphiokine-activated killer cells. J Clin Oncol 1990 ; 7:1138.
44. Rusthoven J, Quirt I, Iscoe N et al. A randomized, placebo-controlled trial comparing BCNU (B), dacarbazine (D), and cisplatin (P) versus BDP and high-dose tamoxifen in the treatment of metastatic melanoma. Thirty-first annual meeting ASCO 1995 ; 14:413 (abs 1309).
45. McClay EF, Mastrangelo MJ, Sprandio JD et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989 ; 63:1292.
46. McClay EF, Mastrangelo MJ, Sprandio JD et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989 ; 63:1292.
47. Legha SS, Papadopoulos NEJ, Plager C et al. Clinical evaluation of recombinant interferon-α2A (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 1987 ; 5:1240.
48. McElwain TJ, Hedley DW, Gordon MY et al. High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma Exp Hematol 1979 ; 7 (suppl):360.
49. Wolff SN, Herzig RH, Fay JW et al. High dose thiotepa with autologous bone marrow transplantation for metastatic melanoma : results of phase I-II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 1989 ; 7:245.
50. Philips GL, Fay JW, Herz GP et al. Intensive 1,3-bis (2-chlorocthyl)-1 nitrosourea (BCNU), NSC-409962 and Cryopreserved autologous marrow transplantation for refractory cancer : a phase I-II study. Cancer 1983 ; 52:1792.
51. Thatcher N, Lind M, Morgenstein G et al. High dose double alkylating agent chemotherapy with DTIC, melphalan or ifosfamide and narrow rescue for metastatic malignant melanoma. Cancer 1989 ; 63:1296.
52. Moormeier JA, Williams SF, Kaminer LS et al. High-dose tri-alkylator chemotherapy with autologous stem cell rescue un patients with refractory malignances. JNCI 1990 ; 82:29.
53. Mitchell MS, Kempf RA, Harel W et al. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma. Bull NY Acad Med 1989 ; 65:128.
54. Lotze MT, Malory YL, Raynor AA et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986 ; 58:2764.
55. Webb DE, Austin HA, Belldegrun A et al. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988 ; 30:141.
56. Szybalsky W. X-ray sensitization by halopyrimidines. Cancer Chemother Rep 1974 ; 58:539-57.
57. Hatanaka H, ed. Neutron capture therapy, Proceedings of the Second International Symposium on Neutron Capture Therapy, Teikyo University, Tokyo, October 1985. Nigata, Japan : Nishimura, 1986.
58. Anichini A, Fossati G, Parmiani G. Clonal analysis of cytotoxic T lymphocyte response to autulogous human metastatic melanoma. Int J Cancer 1985 ; 35:683.
59. De Vries JE, Spits H. Cloned cytolytic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation isolation, and analysis of phenotype and specificity. J Immunol 1984 ; 132:510.
60. Hersey P, MacDonald M, Schibeci S et al. Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma : classification based on phenotype, specificity, and inhibition of monoclonal antobodies to T cell structures. Cancer Immunol Immunother 1986 ; 22:15.
61. Fossati G, Anichini A, Parmiani G. Melanoma cell lysis by human CTL clones : differential involvement of T3, T8 and HLA antigens. Int J Cancer 1987 ; 39:689.
62. Anichini A, Fossati G, Parmiani G. Heterogeneity of clones from a human metastatic melanoma detected by autologous cytoxic T lymphocyte clones. J Exp Med 1986; 163:215.
63. Itoh K, Tilden AB, Balch CM. Interleukin-2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanoma. Cancer Res 1986 ; 46:3011.
64. Splitler LE. Clinical trials of immunotoxin. Second International Congress on Monoclonal Antibody 1987 ; 1:26.
65. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanomia. Science 1991 ; 254:1643.
66. Splitler LE, Bel Rio M, Khentigan A et al. Therapy of patients with malignant melanoma uding a monoclonal antimelanoma antibody-rich A chain immunotoxin. Cancer Res 1987 ; 47:1717.
67. Larson SM, Carrasquillo JA. Krohn KA et al. Localization of 131-I labeled p67-specitic Fab fragments in human melanoma as a basis for radiotherapy. J clin Invest 1983 ; 72:2101.
68. Kagesthia T, Chen ZJ, Kim JW et al. Murine anti-idiotypic monoclonal antibodies to syngeneric antihuman high molecular weight-melanoma associated antigen monoclonal antibodies: Development, characterization and clinical application. Pigment Cell Res 1988 ; 1: (suppl) : 185.
69. Schroff RW, Woodhouse CS, Foon KA et al. Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250.000 dalton melanoma-associated antigen. JNCI 1985 ; 74:299.
70. Rosenber SA, Lottz MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989 ; 210:474.
71. Blair S, Flaherty L, Valdivieso M et al. Comparison of high dose interleukin-2 with combined chemotherapy low-dose IL2 in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1991 ; 10:294 (abstr 1031)
72. Demchak PA, Mier JW, Robert JN et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma. A pilot study. J Clin Oncoll 1991 ; 9:30.
73. Hamblin TJ, Davies B, Sadullah S et al. A phase 2 study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2 and alpha-interferon. Proc Am Soc Clin Oncol 1991 ; 10:294 (abstr 1029).
74. Richards JM. Sequential chemoimmunotherapy for metastatic melanoma. Semin Oncol 1991 ; 18 (suppl 7):91.
75. Legha S, Plager C, Ring S et al. A phase II study of biochenmotherapy using interleukin-2 + interferon alpha-2-a in combination with cisplatin, vinblastine and DTIC in patients with metastatic melanoma. Proc Am Soc Clin Oncol 1992 ; 11:343 (abstr 1179).
76. Khayat D, Borel C, Tourami JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alta-2a for metastatic melanoma. J Clin Oncol 1993 ; 11:2173-80.
77. Khayat D, Antoine E, Rixe O et al. Cheminoimmunotherapy of metastatic malignant melanoma. The Sampêtrière Hospital (SOMPS) Experience. Eur J Cancer 1993 ; 29 A (Suppl 5) :S2-5.
78. Richards JM. Sequential chemoimmunotherapy for metastatic melanoma. Semin Oncol 1991 ; 18 (suppl 7):91-5.
79. Legha S, Buzaid AC, Ring S et al. Improved results of treatment of metastatic melanoma with combined use of biotherapy and chemotherapy (BIOCHEMO). Tirtielh annual meeting ASCO 1994 ; 13:394 (abs 1343).
80. Keilholtz U, Scheibenbogen S, Sloelnen E, Saeger HD, Hunstein W. Immunotherapy of metastic melanoma with interferon-alpha and interleukin-2 : pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur J Cancer 1994 : 30A (7):955-8.